Robert Wasserman, MD, joins Rgenix with more than 20 years of oncology clinical development experience and prior senior roles in the biopharma industry.
Wasserman will oversee new Phase 1b/2 trial of lead compound RGX-104 in lung cancer patients; and RGX-202 Phase 1b/2 trial in patients with colorectal and gastric cancer
September 16, 2019 09:30 AM Eastern Daylight Time
NEW YORK–(BUSINESS WIRE)–Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that Robert Wasserman, MD, has joined the Rgenix management team as its new Chief Medical Officer. Dr. Wasserman takes on his new role after a 20-year career that includes senior positions at large pharma companies including Roche, Novartis and Merck.
In his new role, Dr. Wasserman will have oversight of clinical development for Rgenix’s two lead clinical programs, RGX-104 and RGX-202. In particular, he will oversee the imminent launch of a Phase 1b/2 trial of Rgenix’s lead therapy, RGX-104, a first-in-class oral LXR agonist that has demonstrated anti-tumor activity as a single agent and in combination with other therapies – including chemotherapy and checkpoint blockade – in patients with refractory cancers READ MORE AT BUSINESS WIRE..
